These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25465421)

  • 1. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold.
    Karanasos A; Simsek C; Gnanadesigan M; van Ditzhuijzen NS; Freire R; Dijkstra J; Tu S; Van Mieghem N; van Soest G; de Jaegere P; Serruys PW; Zijlstra F; van Geuns RJ; Regar E
    J Am Coll Cardiol; 2014 Dec; 64(22):2343-56. PubMed ID: 25465421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term favorable coronary healing after bioresorbable scaffold implantation: insights from OCT.
    Gonzalo N; Dangas G; Ibanez B
    J Am Coll Cardiol; 2014 Dec; 64(22):2357-9. PubMed ID: 25465422
    [No Abstract]   [Full Text] [Related]  

  • 4. Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry.
    La Manna A; Miccichè E; D'Agosta G; Tensol Rodrigues Pereira G; Attizzani GF; Capranzano P; Capodanno D; Tamburino C
    Int J Cardiol; 2018 Feb; 253():45-49. PubMed ID: 29137819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
    Serruys PW; Onuma Y; Garcia-Garcia HM; Muramatsu T; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Ormiston JA
    EuroIntervention; 2014 Mar; 9(11):1271-84. PubMed ID: 24291783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
    Diletti R; Karanasos A; Muramatsu T; Nakatani S; Van Mieghem NM; Onuma Y; Nauta ST; Ishibashi Y; Lenzen MJ; Ligthart J; Schultz C; Regar E; de Jaegere PP; Serruys PW; Zijlstra F; van Geuns RJ
    Eur Heart J; 2014 Mar; 35(12):777-86. PubMed ID: 24394380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
    Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
    EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing.
    Džavík V; Colombo A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):81-8. PubMed ID: 24332424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.
    Gutiérrez-Chico JL; Gijsen F; Regar E; Wentzel J; de Bruyne B; Thuesen L; Ormiston J; McClean DR; Windecker S; Chevalier B; Dudek D; Whitbourn R; Brugaletta S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2012 Apr; 5(4):428-35. PubMed ID: 22516401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.
    Onuma Y; Serruys PW; Perkins LE; Okamura T; Gonzalo N; García-García HM; Regar E; Kamberi M; Powers JC; Rapoza R; van Beusekom H; van der Giessen W; Virmani R
    Circulation; 2010 Nov; 122(22):2288-300. PubMed ID: 20975003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
    Gomez-Lara J; Brugaletta S; Diletti R; Garg S; Onuma Y; Gogas BD; van Geuns RJ; Dorange C; Veldhof S; Rapoza R; Whitbourn R; Windecker S; Garcia-Garcia HM; Regar E; Serruys PW
    Eur Heart J; 2011 Feb; 32(3):294-304. PubMed ID: 21123276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
    Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
    Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification.
    Okamura T; Onuma Y; García-García HM; Regar E; Wykrzykowska JJ; Koolen J; Thuesen L; Windecker S; Whitbourn R; McClean DR; Ormiston JA; Serruys PW;
    JACC Cardiovasc Interv; 2010 Aug; 3(8):836-44. PubMed ID: 20723856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.
    Farooq V; Serruys PW; Heo JH; Gogas BD; Onuma Y; Perkins LE; Diletti R; Radu MD; Räber L; Bourantas CV; Zhang Y; van Remortel E; Pawar R; Rapoza RJ; Powers JC; van Beusekom HM; Garcìa-Garcìa HM; Virmani R
    JACC Cardiovasc Interv; 2013 May; 6(5):523-32. PubMed ID: 23702016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?
    Brugaletta S; Radu MD; Garcia-Garcia HM; Heo JH; Farooq V; Girasis C; van Geuns RJ; Thuesen L; McClean D; Chevalier B; Windecker S; Koolen J; Rapoza R; Miquel-Hebert K; Ormiston J; Serruys PW
    Atherosclerosis; 2012 Mar; 221(1):106-12. PubMed ID: 22209268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.